A pharmacometric approach to evaluate drugs for potential repurposing as COVID-19 therapeutics by Wattanakul, T, Chotsiri, P, Scandale, I, Hoglund, RM, Tarning, J

Drug development for the treatment of onchocerciasis: population pharmacokinetic and adverse events modeling of emodepside by Assmus, F, Hoglund, RM, Monnot, F, Specht, S, Scandale, I, Tarning, J

State-of-the-Art in the Drug Discovery Pathway for Chagas Disease: A Framework for Drug Development and Target Validation by Gabaldón-Figueira JC, Martinez-Peinado N, Escabia E, Ros-Lucas A, Chatelain E, Scandale I, Gascon J, Pinazo MJ, Alonso-Padilla J

Get full text

The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV- 2 variants of concern by Abdelnabi, R, Foo, CS, Jochmans, D, Vangeel, L, De Jonghe, S, Augustijns, P, Mols, R, Weynand, B, Wattanakul, T, Hoglund, RM, Tarning, J, Mowbray, CE, Sjö, P, Escudié, F, Scandale, I, Chatelain, E, Neyts, J

Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2 by Driouich, J-S, Cochin, M, Touret, F, Petit, P-R, Gilles, M, Moureau, G, Barthélémy, K, Laprie, C, Wattanakul, T, Chotsiri, P, Hoglund, RM, Tarning, J, Fraisse, L, Sjö, P, Mowbray, CE, Escudié, F, Scandale, I, Chatelain, E, de Lamballerie, X, Solas, C, Nougairède, A

Need for a standardized translational drug development platform: lessons learned from the repurposing of drugs for COVID-19 by Assmus, F, Driouich, J-S, Abdelnabi, R, Vangeel, L, Touret, F, Adehin, A, Chotsiri, P, Cochin, M, Foo, CS, Jochmans, D, Kim, S, Luciani, L, Moureau, G, Park, S, Pétit, P-R, Shum, D, Wattanakul, T, Weynand, B, Fraisse, L, Ioset, J-R, Mowbray, CE, Owen, A, Hoglund, RM, Tarning, J, Lamballerie, XD, Nougairède, A, Neyts, J, Sjö, P, Escudié, F, Scandale, I, Chatelain, E